9 Meters Biopharma announced the discontinuation of their Phase 3 clinical trial for larazotide after an independent analysis showed that the number of patients needed to determine a significant clinical outcome between larazotide and the placebo was too large to support continuing the trial. CedLara® was being developed for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet. Read the press release here.
This study analyzing hospitalizations from 2007 to 2017 "noted a rising trend in hospitalizations, inpatient mortality, and hospital costs for CeD [celiac disease] hospitalizations in the US; however, inpatient EGDs [esophagogastroduodenoscopies] performed and mean LOS [length of stay] showed a decline."
This study looked into the connection between celiac disease and inflammatory bowel disease and concluded, "The bidirectional association between CeD diagnosis and IBD warrants attention in the initial assessment and follow-up of these conditions. Their co-occurrence, independent of temporal sequence, suggests shared etiology."
Dr. Alessio Fasano, the W. Allan Walker Chair of Pediatric Gastroenterology and Nutrition and Chief of the Division of Pediatric Gastroenterology and Nutrition at MassGeneral Hospital for Children, discusses the microbiome in this video.